… Olodaterol (OLO) is a novel once-daily LABA bronchodilator that was effective in lung … dual
long-acting bronchodilators (UME/VIL, IND/GLY, and TIO/OLO) used on patients with COPD …

… in development for chronic obstructive pulmonary disease. This … None of the patients had a
history of asthma. The protocol … rate at efficacious and long-acting doses, which confirmed the …

… COPD suggesting their adoption in the chronic treatment of COPD combined with long-acting
bronchodilators … of both asthma and COPD, Citation61 namely subjects with a history of …

… developed for use in COPD. Further studies would be required to confirm the efficacy of
navafenterol in patients with COPD and in patients with severe asthma in combination with an …

… for COPD recommends that the majority of patients are initially treated with a long-acting
bronchodilator … 2 inflammation biomarker to confirm asthma-like features in patients with COPD. …

… Most of the novel therapeutic agents result from the … ICS withdrawal in COPD patients with
an asthmatic component is related … Long-acting bronchodilators are the central part of COPD …

… periphery) of ICS/LABA with NEXThaler in healthy volunteers, and patients with asthma
and COPD using a gamma-scintigraphy technique, (41) supporting the validity of our findings. …

… Chronic obstructive pulmonary disease (COPD) and asthma … 3.2 million deaths from COPD
and 0.4 million from asthma [1], … , and bronchodilator therapy is a key component of this. In …

… -COPD, our results showed that patients with BE-COPD might receive additional benefit from
regular treatment with long-acting bronchodilators … and long-acting bronchodilator effects. …

… COPD, including long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs]
and/or long-acting … history of asthma, whereas patients with a history of asthma were excluded …